Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
65.80    0.90 (1.39%)
Bid:
65.40
Ask:
65.60
Spread: 0.20 (0.306%)
Market Cap: £581.30m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Directorate Change

14 Dec 2017 16:48

RNS Number : 4224Z
IP Group PLC
14 December 2017
 

FOR RELEASE ON

14 December 2017

 

 

IP Group plc - Retirement of Non-executive Director

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), a leading developer of intellectual property-based businesses, announces that Doug Liversidge, CBE, will retire from his position as a non-executive director of the Company at the end of the year.

 

Mr Liversidge has served on the Board in a non-executive capacity since March 2014 following IP Group's acquisition of Fusion IP plc, where he was Chairman. He became Senior Independent Director of IP Group in March 2015.

 

Professor David Begg, who was appointed as a non-executive director in October 2017, will become Senior Independent Director with effect from 1 January 2018.

 

Mike Humphrey, Non-executive Chairman, said: "I would like to thank Doug both for his contribution to the Group and his wise counsel. He has played an important role in aiding the successful integration of Fusion IP and the Group's growth since that time and we wish him all the very best in his retirement."

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Alan Aubrey, Chief Executive OfficerGreg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

Andrew Wilson

Martha Walsh

+44 (0) 7810 636995

+44 (0) 7876 245962

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across four main sectors -- Biotech, Cleantech, Healthcare and Technology. The Company, which recently announced the acquisition of Touchstone Innovations plc, is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATIBFTMBIBBIR
Date   Source Headline
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m
12th May 202112:08 pmRNSHolding(s) in Company
10th May 202111:15 amRNSInvestor webinars
6th May 20216:13 pmRNSNotice of AGM, Annual Report, Scrip Dividend
6th May 20215:55 pmRNSLTIP & DBSP awards; Director/PDMR shareholding
5th May 20217:00 amRNSPortfolio company Inivata acquired by NeoGenomics
5th May 20217:00 amRNSPortfolio company Kuur acquired by Athenex
4th May 20217:00 amRNSPortfolio company Oxford Nanopore raises £195m
7th Apr 202111:27 amRNSDirector/PDMR Shareholding
31st Mar 20219:15 amRNSHolding(s) in Company
30th Mar 20217:05 amRNSOxford Nanopore announces preparing for IPO in H2
26th Mar 202112:26 pmRNSEMA positive opinion for Diurnal's Chronocort
10th Mar 20217:00 amRNSAnnual Results
4th Mar 20216:07 pmRNSHolding(s) in Company
2nd Mar 202112:03 pmRNSHolding(s) in Company
24th Feb 202110:33 amRNSNotice of Results
18th Feb 20214:31 pmRNSHolding(s) in Company
18th Feb 20218:00 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSPortfolio company ApcinteX acquired by Centessa
10th Feb 20217:00 amRNSIP Group, Inc. raises $50.0m (£36.5m*) of funding
9th Feb 20213:52 pmRNSHolding(s) in Company
2nd Feb 20215:15 pmRNSHolding(s) in Company
11th Jan 20215:29 pmRNSHolding(s) in Company
6th Jan 20214:57 pmRNSPortfolio co Hinge Health completes $300m round
6th Jan 202111:34 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSPortfolio co Oxbotica completes £36m funding round
4th Dec 202011:41 amRNSHolding(s) in Company
3rd Dec 20208:01 amRNSArtios and Merck in global strategic collaboration
25th Nov 20207:00 amRNSDirector Declaration
23rd Nov 20205:05 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSInvestor webinar
13th Oct 20207:00 amRNSOxford Nanopore funding round and contract win
9th Oct 20209:46 amRNSOxford Nanopore's LamPORE test gains CE-IVD mark
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company
15th Sep 202012:07 pmRNSSecond Price Monitoring Extn
15th Sep 202012:02 pmRNSPrice Monitoring Extension
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
1st Sep 20205:18 pmRNSForm 8.3 - Modern Water plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.